Latest Conference Articles

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

The next-generation KRAS G12C inhibitor MK-1084 showed promising efficacy and safety as a single agent and in combinations for advanced colorectal cancer.

Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

DNA methylation, RTK pathway changes, and KRAS amplifications may drive resistance to sotorasib plus panitumumab in KRAS G12C colorectal cancer.

Escalated adjuvant chemotherapy, guided by ctDNA, did not improve recurrence-free survival for stage III colon cancer patients, per DYNAMIC-III trial.

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Nivolumab plus ipilimumab shows durable survival benefit over chemotherapy and monotherapy in mismatch repair-deficient colorectal cancer.

Anlotinib plus chemotherapy has emerged as a first-line alternative to bevacizumab/chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer.

The BREAKWATER trial showed encorafenib, cetuximab, & mFOLFOX6 significantly improved PFS and OS in first-line BRAF V600E-mutant mCRC.

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy, improving survival without disease progression.

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.

T-DXd significantly improved overall survival vs ramucirumab/paclitaxel in second-line HER2-positive unresectable/metastatic gastric/GEJ cancer.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Christopher Danes, PhD, discusses how patient and caregiver priorities and concerns vary during the course of treatment for non–small cell lung cancer.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

Christopher Danes, PhD, discusses a study exploring the differences in priorities for patients and their caregivers when undergoing treatment for non–small cell lung cancer.

Ayal Aizer, MD, MHS, discusses the unmet needs in treating patients with brain metastases.

Neel Shah, MD, and Manmeet Ahluwalia, MD, MBA, FASCO, discuss what they look most forward to hearing about and learning at the 2025 ASCO Annual Meeting.

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running high over a wave of potential practice-changing data sets to be unveiled.

The ASCO 2025 press briefing showcased early highlights in cancer therapy. Here’s what you need to know.

A large study found GLP-1 drugs don't raise cancer risk; instead, they cut obesity-related cancers by 7% and overall mortality by 8%.

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.

Olalekan O Oluwole, MD, MBBS, discusses a study investigating shorter monitoring times post CAR T therapy.

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting optimized dosing strategies.

Felix Guerrero-Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.